Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 3/20 | 0.39 |
| ▸ | JAK1 | P23458 | 3/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 9/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.35 |
| ▸ | ABL1 | P00519 | 3/20 | 0.35 |
| ▸ | AKT1 | P31749 | 2/20 | 0.34 |
| ▸ | AKT2 | P31751 | 2/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | LTK | P29376 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | PRKX | P51817 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3599442 | 0.81 | NUDT1 (0.63) | NUDT1JAK1CHEK1CHEK2ABL1 | |
| SCHEMBL12078774 | 0.76 | NUDT1 (0.66) | NUDT1JAK1EGLN2KDM4EALDH1A1 | |
| SCHEMBL2252174 | 0.74 | NUDT1 (0.46) | NUDT1JAK1EGLN2KDM4EALDH1A1 | |
| SCHEMBL15268998 | 0.72 | FYN (0.46) | NUDT1CHEK1 | |
| SCHEMBL30263697 | 0.71 | TUBB4A (0.50) | JAK1KDM4EALDH1A1 | |
| SCHEMBL18202876 | 0.71 | CHEK1 (0.38) | NUDT1JAK1CHEK1CHEK2ABL1 | |
| SCHEMBL15269196 | 0.71 | JAK1 (0.56) | NUDT1JAK1EGLN2KDM4EALDH1A1 | |
| SCHEMBL25646677 | 0.70 | LRRK2 (0.40) | NUDT1JAK1LRRK2 | |
| SCHEMBL2634433 | 0.69 | PIK3CG (0.54) | NUDT1JAK1 | |
| SCHEMBL15269263 | 0.69 | NUDT1 (0.55) | NUDT1JAK1EGLN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4041731-B1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORP (US) | 2026-02-18 | — | — | EP | claimed |
| US-20260022119-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022119-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CCNA1, CDK1, CCNE1 | NUDT1 1340/4885JAK1 1378/4885CHEK1 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.